Form 4: IGM Biosciences Executive Harler Mary Beth Reports Changes in Beneficial Ownership

Mary Beth Harler, Head of Research & Autoimmunity at IGM Biosciences, reports transactions involving restricted stock units (RSUs) and stock options.

Summary

• On July 19, 2024, Mary Beth Harler, Head of Research & Autoimmunity at IGM Biosciences, engaged in transactions involving the company's stock.
• Harler acquired 54,999 restricted stock units (RSUs) that vest over time, starting July 19, 2025.
• She also acquired 25,001 RSUs that vest starting January 19, 2026.
• These RSU grants were issued in exchange for the cancellation of her options to purchase 200,000 shares of IGM Biosciences' common stock as part of the company's option exchange program.
• Following these transactions, Harler directly owns 165,227 shares of common stock.
• She no longer holds the options to purchase 200,000 shares.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.

Positives

• The executive's continued holding of shares and RSUs demonstrates ongoing alignment with the company's success.

Industry Context

This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies like IGM Biosciences. It provides transparency into the equity holdings of key personnel.

Comparison to Industry Standards

• Option exchange programs are a fairly common practice in the biotech industry to refresh equity incentives and align executive compensation with current market conditions.
• Vesting schedules for RSUs, such as the quarterly vesting after an initial period, are standard practice to retain employees and incentivize long-term performance.
• Companies like Amgen, Biogen, and Regeneron also regularly disclose similar Form 4 filings related to their executives' stock transactions.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect internal compensation adjustments.
• Employees may be indirectly affected by the option exchange program, which aims to optimize the company's equity incentive structure.

Key Dates